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Aim: Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose 
adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with 
type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy 
(metformin, teneligliptin, and glimepiride) plus diet/exercise therapy.
Methods: Forty patients on stable triple therapy were randomized to glimepiride dose 
adjustment without (glimepiride group) or with add-on canagliflozin 100 mg (canagliflozin 
group) for 24 weeks. The glimepiride dose was adjusted every 4 weeks based on continuous 
glucose monitoring over the previous 2 weeks according to a prespecified algorithm. After 
the 24-week treatment period, the patients returned to the pre-intervention regimen for 1 
week (wash-out period). Patients underwent 75 g OGTTs at the start of the run-in period and 
at the end of the wash-out period. The primary endpoint was the change in disposition index 
(DI).
Results: Thirty-nine patients completed the study (canagliflozin, n = 19; glimepiride, n = 
20). The change in DI was +5.1% and −11.0% in the canagliflozin and glimepiride groups, 
respectively, with a between-group difference ratio of 18.0% (P = 0.330). HbA1c, fasting 
plasma glucose, body weight, and daily-life continuous glucose monitoring-derived para-
meters improved in the canagliflozin group. Hypoglycemia occurred in 60% (44 episodes) 
and 70% (79 episodes) of patients in the canagliflozin and glimepiride groups, respectively. 
The change in DI was significantly correlated with the changes in glycemic control and 
variability in overall cohort.
Conclusion: Adding canagliflozin to the triple therapy improved beta cell function by 18%, 
but it did not reach statistical significance. This study also demonstrated a correlation 
between the change in DI and glycemic control. As canagliflozin improved both glucose 
level and variability with relatively lower risk of hypoglycemia compared with glimepiride 
dose adjustment, adding canagliflozin to the triple therapy may be clinically beneficial.
Trial Registration: UMIN000030208/jRCTs051180036.
Keywords: beta cell function, canagliflozin, glimepiride, glycemic control, type 2 diabetes 
mellitus
Introduction
Type 2 diabetes mellitus is characterized by progressive impairments in pancreatic beta 
cell function,1–4 with an estimated decrease of about 25% over 5 years.2 The deteriora-
tion in glycemic control itself also aggravates pancreatic beta cell function, so-called 
glucotoxicity, leading to a vicious cycle.5 As a consequence, the proportion of patients 
who achieve their glycated hemoglobin (HbA1c) target decreases with longer diabetes 
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duration, despite increases in the number of prescribed anti-
hyperglycemic agents.6–8 However, once hyperglycemia is 
appropriately corrected, it may be possible to eliminate glu-
cotoxicity and ameliorate pancreatic beta cell function.9,10 
Therefore, it is important to preserve beta cell function using 
appropriate antihyperglycemic agents.
Metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, 
and sulfonylureas (especially glimepiride) are commonly 
used in clinical practice.11–13 If patients taking these three 
agents require further treatment intensification, increasing 
the sulfonylurea dose is an option. However, sulfonylureas 
are associated with increased risk of hypoglycemia,14,15 
especially at high doses,16 necessitating continued vigi-
lance for hypoglycemia. By comparison, sodium–glucose 
cotransporter-2 (SGLT2) inhibitors, with a different anti-
hyperglycemic mechanism, have the potential to be com-
bined with commonly used antihyperglycemic agents.17–21 
Adding an SGLT2 inhibitor may be an effective alternative 
to adjusting the glimepiride dose in such patients.
Some studies have suggested that SGLT2 inhibitors may 
confer improvements in beta cell function.22 It is desirable that 
beta cell function is evaluated as insulin secretion adjusted for 
whole-body insulin sensitivity, because insulin secretion has a 
hyperbolic relationship with whole-body insulin sensitivity.23 
The disposition index (DI), the product of the insulin response 
to glucose and insulin sensitivity indices, has emerged as a 
valuable tool for the purpose of evaluating beta cell function.24 
In fact, a short-term pilot study recently demonstrated that 
administration of an SGLT2 inhibitor improved beta cell func-
tion measured as DI.25
Currently, however, it is unknown whether adjusting the 
sulfonylurea dose or adding an SGLT2 inhibitor is more 
beneficial in terms of preserving beta cell function and glyce-
mic control in patients with type 2 diabetes on triple therapy. 
Therefore, we performed a randomized, open-label, parallel- 
group trial to compare the effects of add-on canagliflozin with 
glimepiride dose adjustment and glimepiride dose adjustment 
on pancreatic beta cell function measured in terms of the DI, in 
patients with type 2 diabetes with inadequate glycemic control 
despite stable triple therapy (metformin, teneligliptin, and 
glimepiride) plus diet and exercise therapy. We also explored 
which factors are related to the improvement in DI.
Methods
Ethics
The study was conducted in compliance with the 
Declaration of Helsinki and the Clinical Trials Act (Act 
No. 16 of April 14, 2017). The study was approved by the 
Institutional Review Board and was registered with the 
University Hospital Medical Information Network 
Clinical Trials Registry (UMIN-CTR, UMIN000030208) 
on March 28, 2018. However, due to the new Clinical 
Research Act enforced on April 1, 2018, in Japan, studies 
not completed by March 31, 2019, were required to be re- 
reviewed by a Certified Review Board and re-registered on 
the Japan Registry of Clinical Trials (jRCT). Therefore, 
this study was re-reviewed by Osaka University Clinical 
Research Review Committee, and re-registered with the 
jRCT on January 29, 2019 (jRCTs051180036).
Patients
Patients aged 20–74 years who provided informed consent 
and who had not achieved their individual glycemic target 
according to Japanese guidelines26 despite unchanged diet 
and exercise therapy over 12 weeks and stable doses of 
metformin (0–2250 mg/day), teneligliptin (20 mg/day), 
and glimepiride (0.5–2 mg/day) over 12 weeks were eli-
gible for the study.
Patients with any of the following were excluded: type 
1 diabetes mellitus, need for insulin therapy, history of 
hypersensitivity to canagliflozin, history of heart failure 
(New York Heart Association class IV), estimated glomer-
ular filtration rate <45 mL/min/1.73 m2, severe hepatic 
dysfunction, pregnancy, nursing or planning to become 
pregnant during the study, suspected or diagnosed malig-
nant tumors, participating in another interventional study, 
and considered by the investigator to be inappropriate for 
the study for any other reason.
Concomitant use of the following drugs was prohibited 
from 12 weeks before the study to the end of the study: 
insulin, sulfonylureas other than glimepiride, glinides, 
biguanides other than metformin, DPP-4 inhibitors other 
than teneligliptin, GLP-1 receptor agonists, SGLT2 inhibi-
tors except for canagliflozin during the treatment period 
and newly launched antidiabetic drugs or investigational 
products. Patients could use α-glucosidase inhibitors or 
thiazolidinediones provided that they were started more 
than 12 weeks before the run-in period and was planned 
to continue administration at the same dose until the end of 
the study.
Study Design
This study was performed at Shiraiwa Medical Clinic 
(Osaka, Japan). It comprised a 2–4 week run-in period, a 
24-week treatment period, and a 1-week wash-out period. 
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At the start of the run-in period, the participants underwent 
a 75 g oral glucose tolerance test (OGTT). After the run-in 
period, they were randomized 1:1 to the glimepiride group 
(glimepiride dose adjustment) or the canagliflozin group 
(add-on canagliflozin 100 mg and glimepiride dose adjust-
ment) using a dynamic allocation method stratified by the 
OGTT-derived DI and the glimepiride dose at the start of 
the run-in period. Randomization was performed by cen-
tral registration with an online registration system. In both 
groups, teneligliptin and metformin were continued at the 
same doses. Patients visited the clinic every 4 weeks. 
Twenty-four-hour blood glucose levels in daily life were 
monitored for 2 weeks after each visit by continuous 
glucose monitoring (CGM; FreeStyle Libre Pro; Abbott). 
The glimepiride dose was adjusted according to the pre-
scribed algorithm based on the CGM data (Table S1) at the 
next visit. At the end of the treatment period, the patients 
returned to the regimen they had used in the run-in period 
for 1 week (wash-out period). The patients underwent a 75 
g OGTT at the end of the wash-out period.
Prior to the OGTTs, the patients fasted for more than 
10 h and were asked to refrain from taking the study drugs, 
concomitant medications, or restricted medications (α-glu-
cosidase inhibitors, thiazolidines). Patients drank Trelan-G 
solution (=75 g of glucose) within 5 min, and blood 
samples were obtained at 0 min, 30 min (±5 min), 60 
min (±10 min), and 120 min (±10 min).
The primary endpoint of this study was the change in 
DI from baseline to week 25. DI was calculated as 
(IAUCIns0–120/IAUCGlu0–120) × (Matsuda index), where 
IAUCIns0–120 and IAUCglu0–120 are the incremental areas 
under the insulin and glucose curves, respectively, from 0 
to 120 min.10,24,25,27 As the insulin secretion index and 
Matsuda index (index of insulin resistance) tend to be 
influenced by SGLT2 inhibitors,25 wash-out of the 
SGLT2 inhibitor is needed to evaluate the change in beta 
cell function after treatment. The effect of canagliflozin 
(100 mg) on urinary glucose excretion is mostly abolished 
by 3 days after stopping administration.28 Therefore, we 
assessed the post-treatment DI after a 1-week wash-out to 
exclude the influence of canagliflozin on the calculation of 
DI from an OGTT. Secondary endpoints were changes in 
HbA1c, fasting plasma glucose (FPG), body weight, gly-
cemic parameters derived from CGM, and glimepiride 
doses. Glycemic parameters derived from CGM data 
were the mean glucose, glucose standard deviation (SD), 
mean amplitude of glucose excursions (MAGE), total area 
for the range of glucose variability, and the proportion of 
time spent with glucose in hypoglycemic (≤70 mg/dL, 
≤3.89 mmol/L; <54 mg/dL, <3.00 mmol/L), normoglyce-
mic (>70 to <180 mg/dL, >3.89 to <9.99 mmol/L), and 
hyperglycemic (≥180 mg/dL, ≥9.99 mmol/L) ranges. 
Safety evaluations include assessments of adverse events 
(AEs) described using the Medical Dictionary for 
Regulatory Activities/Japanese version 21.0 and laboratory 
variables. Hypoglycemia was defined as a blood glucose 
level of ≤70 mg/dL (≤3.89 mmol/L) measured using an in- 
hospital blood sample, a CGM level of ≤70 mg/dL 
(≤3.89 mmol/L), or the presence of symptoms of 
hypoglycemia.
Determination of Sample Size
For the change in DI from baseline to the week 25, we 
estimated a mean difference in the log(DI) of 0.48 (i.e. 
1.62-fold of intergroup ratio; difference ratio 62%) with 
an SD of 0.49 in the canagliflozin add-on group versus 
the glimepiride group based on an unpublished sub-group 
analysis using data for patients with an HbA1c of 7.0–8.0% 
(53.01–63.94 mmol/mol) in the TA-7284-05 study.17,29 We 
estimated that a sample size of 17 patients per group was 
needed to achieve a power of 80%. Taking into considera-
tion the number of withdrawals, the target sample size was 
set at 40 patients (20 patients/group).
Statistical Analyses
Efficacy was analyzed using the full analysis set, which 
included all patients in whom DI was calculated in both 
the run-in and wash-out periods. Safety was assessed using 
the safety analysis set, which included all randomized 
patients, excluding any patients who did not receive any 
dose of canagliflozin or glimepiride.
Data are presented as the least squares mean (LS mean) 
with 95% CIs, geometric mean with 95% CI, or mean with 
SD. Because DI was expected to show a right-skewed 
distribution, the values were log-transformed prior to 
data analysis. Some secondary variables demonstrating a 
right-skewed distribution were also log-transformed. 
Comparisons between the canagliflozin and glimepiride 
groups for the change from baseline were made using 
ANCOVA with the baseline level as the covariate. Anti- 
log transformation (exponential transformation) was per-
formed to calculate the post/pre-dose ratios and the inter-
group ratios (canagliflozin group/glimepiride group) with 
95% CIs. The post/pre-percent change (%) or intergroup 
difference (%) was calculated as one subtracted from these 
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values and multiplied by 100. Similar analyses were made 
for the DI-related items.
For intergroup comparisons of HbA1c, FPG, and body 
weight, the change at the last time point (last observation 
carried forward, LOCF) was analyzed with the baseline level 
as a covariate, and the LS mean changes with 95% CIs are 
shown. For the glimepiride dose and CGM-derived parameters 
(mean, SD, MAGE, and total area for the range of glucose 
variability), the LS mean changes from baseline with 95% CIs 
are shown. For the changes at 24 weeks after administration or 
at 1 week after the treatment period, ANCOVA was performed 
using the baseline level as the covariate. Similarly, the changes 
at each time point were also analyzed as the reference. The 
mean and SD for the time course of the proportion of time in 
hypoglycemic (≤70 mg/dL, ≤3.89 mmol/L; <54 mg/dL, 
<3.00 mmol/L), normoglycemic (>70 to <180 mg/dL, >3.89 
to <9.99 mmol/L), and hyperglycemic (≥180 mg/dL, 
≥9.99 mmol/L) ranges were determined from CGM data. 
The correlations between log(DI) and secondary endpoints 
using Pearson’s correlation coefficient were determined in 
the canagliflozin group, glimepiride group, and in the overall 
cohort. The proportions of time in hypoglycemic, normogly-
cemic, and hyperglycemic ranges on CGM, and the correla-
tions between log(DI) and secondary endpoints in the overall 
cohort were assessed in post hoc analyses.
All statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute, Cary, NC, USA). Data manage-
ment and statistical analyses were conducted by EP-CRSU 
Co., Ltd. (Tokyo, Japan).
Results
Patients
Between April 24 and August 29, 2018, a total of 40 patients 
were recruited, enrolled, and randomized to the two groups, 
with 20 patients per group (Figure S1). Thirty-nine patients 
completed the treatment period. One patient allocated to the 
canagliflozin group was withdrawn because this patient was 
found to meet an exclusion criterion (diagnosis of a malig-
nant tumor or suspected malignant tumor) following rando-
mization. Therefore, the canagliflozin group comprised 19 
patients for efficacy analyses and 20 patients for safety 
analyses. Both groups were well balanced in terms of base-
line characteristics (Table 1).
Βeta Cell Function and Glycemic Control
The mean daily glimepiride dose decreased steadily in 
both groups, from about 0.8 mg per day at baseline to 
0.069 mg in the canagliflozin group and 0.188 mg in the 
glimepiride group (Figure 1A). Overall, 15/19 and 12/20 
patients in the canagliflozin and glimepiride groups, 
respectively, stopped glimepiride use during the treatment 
period. The between-group difference of glimepiride dose 
in the LS mean at week 24 was −0.119 mg (95% CI 
−0.286 to 0.048, P = 0.158).
As shown in Figure 1B, HbA1c decreased from baseline to 
week 24 in the canagliflozin group but increased in the glime-
piride group, with a significant difference in LS mean of 
−0.72% at the LOCF (95% CI −1.20% to −0.24%, 
P = 0.005) (−7.9 [−13.1 to −2.6] mmol/mol). A significant 
reduction in FPG was observed in the canagliflozin group, 
with a difference in LS mean of −27.0 mg/dL at the LOCF 
Table 1 Patient Characteristics (Full Analysis Set)
Canagliflozin Glimepiride
N 19 20
Males, n (%) 9 (47.4) 10 (50.0)
Females, n (%) 10 (52.6) 10 (50.0)
Age, years 59.4 (8.66) 54.8 (9.70)
Duration of diabetes, years 10.95 (7.08) 11.48 (8.33)
Body weight, kg 66.71 (11.66) 69.43 (19.63)
BMI, kg/m2 26.05 (3.90) 26.13 (5.03)
Complications, n (%)
Diabetic retinopathy 3 (15.8) 3 (15.0)
Diabetic nephropathy 0 (0.0) 4 (20.0)
Diabetic neuropathy 8 (42.1) 10 (50.0)
Hypertension 9 (47.4) 12 (60.0)
Dyslipidemia 15 (78.9) 15 (75.0)
HbA1c, % 7.95 (0.76) 7.60 (0.52)
mmol/mol 63.39 (8.31) 59.57 (5.68)
FPG, mg/dL 150.3 (28.1) 137.4 (24.4)
mmol/L 8.34 (1.56) 7.63 (1.35)
Metformin dose, mg 684.2 (298.6) 1087.5 (580.8)
Teneligliptin dose, mg 20.0 (0.0) 20.0 (0.0)
Glimepiride dose, mg 0.789 (0.481) 0.800 (0.470)
Use of other antihyperglycemic 
agents
α-glucosidase inhibitors
n (%) 2 (10.5) 5 (25.0)
Dose, mg 0.600* 0.575 (0.183)
Thiazolidinediones
n (%) 0 (0.0) 0 (0.0)
Notes: Data are number (percent) of patients or mean (SD). *SD was not 
calculated because two patients used α-glucosidase inhibitors in the canagliflozin 
group. 
Abbreviations: SD, standard deviation; BMI, body mass index; HbA1c, glycated 
hemoglobin; FPG, fasting plasma glucose.
Takahara et al                                                                                                                                                        Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                           

















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
(95% CI −47.3 to −6.6 mg/dL, P = 0.011) (−1.50 [−2.63 to 
−0.37] mmol/L) (Figure 1C). Although body weight decreased 
in both groups, the magnitude of the decrease at LOCF was 
greater in the canagliflozin group (LS mean: −4.03 vs −1.88 
kg; difference in LS mean: −2.15 kg, 95% CI −3.46 to −0.84 
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Figure 1 Glimepiride doses over the preceding 4 weeks (A) and changes in HbA1c (B), FPG (C), body weight (D), and percent change in DI (E) from baseline. Notes: 
Values are presented as the mean ± SD (A), LS mean ± 95% CI (B–D), or intergroup ratio with 95% CI (E). *P < 0.05 vs the glimepiride group (ANCOVA). Canagliflozin 
group n = 19, glimepiride group n = 20, unless otherwise indicated. †n = 18 at week 24. HbA1c: IFCC value (mmol/mol) = 10.93 × NGSP value (%) − 23.5. Glucose: 1 mg/dL 
= 0.0555 mmol/L.  
Abbreviations: CI, confidence interval; DI, disposition index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IFCC, International Federation of Clinical Chemistry 
and Laboratory Medicine; LOCF, last observation carried forward; LS, least squares; NGSP, National Glycohemoglobin Standardization Program; SD, standard deviation.
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The primary endpoint, the change in DI from baseline to 
week 25, is shown in Figure 1E and Table S2. DI increased 
by 5.1% in the canagliflozin group and decreased by 11.0% 
in the glimepiride group. Although the ratio for the change in 
DI was 18.0% greater in the canagliflozin group, this differ-
ence was not statistically significant (95% CI −16.0% to 
65.9%, P = 0.330).
As DI is calculated from OGTT-associated indices 
(Matsuda index, IAUCIns0–120 and IAUCGlu0–120), we exam-
ined the changes in the indices differently. However, we 
found no significant differences in the changes in these 
indices between the two groups (Table S2).
We also examined the changes in glycemic parameters 
derived from CGM (Figure 2). As illustrated in Figure 2A–D, 
the measures of mean glucose and mean glucose variability 
(SD, MAGE, and total area for the range of glucose varia-
bility) showed tendencies to decrease in the canagliflozin 
group within 4–8 weeks after baseline and remained at 
lower levels compared with the glimepiride group. We 
observed trends toward increased time spent in the normo-
glycemic range and decreased time spent in the hyperglyce-
mic range in the canagliflozin group, whereas the time spent 
in the hypoglycemic range decreased in both groups 
(Figure 2E–H). The proportion of time with nocturnal hypo-
glycemia (0:00–5:59) decreased in both groups (Figure S2).
We next determined the correlations between change in 
log(DI) and efficacy endpoints in the overall cohort (n = 39) 
and in both treatment groups separately (Figure 3). In the 
overall cohort, the change in log(DI) was significantly corre-
lated with the changes in HbA1c (r = −0.448, P = 0.004), 
FPG (r = −0.486, P = 0.002), mean glucose (r = −0.588, 
P < 0.001), MAGE (r = −0.477, P = 0.003) and the propor-
tions of time spent in the hyperglycemic (r = −0.638, P < 
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These correlations were observed in the canagliflozin and 
glimepiride groups individually, except for the change in 
FPG in the canagliflozin group and the changes in HbA1c 
and MAGE in the glimepiride group. The change in log(DI) 
was not correlated with the change in body weight in the 
overall cohort or in either group (Figure 3C).
Safety
Safety was assessed in terms of vital signs, laboratory 
data, and AEs. The changes in laboratory values are 
shown in Table S3. AEs occurred in 20 (100%) and 18 
(90%) patients in the canagliflozin and glimepiride groups, 
respectively, and included serious AEs in one patient in 
each group (hepatic neoplasm in the canagliflozin group 
and hydronephrosis in the glimepiride group) and adverse 
drug reactions in 15 patients in each group (Table S4). 
Hypoglycemia was the most frequent AE, with 44 epi-
sodes occurring in 12 patients (60%) in the canagliflozin 
group and 79 episodes in 14 patients (70%) in the glime-
piride group. Only three episodes of hypoglycemia with 
symptoms were reported in the canagliflozin group and 
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Figure 2 (A–D) Changes in mean glucose (A), glucose SD (B), MAGE (C), and total area for the range of glucose variability (D) determined by CGM. (E–H) The 
proportion of time with glucose levels in hyperglycemic (≥180 mg/dL, ≥9.9 mmol/L, E), normoglycemic (>70 to <180 mg/dL, >3.89 mmol/L to <9.99 mmol/L, F), and 
hypoglycemic (≤70 mg/dL, ≤3.89 mmol/L, G; <54 mg/dL, <3.00 mmol/L, H) ranges, as determined by CGM.  
Notes: The insets in (G and H) show a magnified axis for the proportion of time. CGM was performed over 2 weeks before each 4 weekly visit. Values are presented as the LS mean ± 
95% CI (A–D) or mean ± SD (E–H). *P < 0.05 vs the glimepiride group (ANCOVA). Statistical comparisons of the two groups were not performed in (E–H). Canagliflozin group n = 19 
(A–F) or n = 20 (G and H), glimepiride group n = 20, unless otherwise indicated. †n = 18 at baseline, n = 17 at week 24; ‡n=18 at Week 24; §n = 19 at week 12. Glucose: 1 mg/dL = 
0.0555 mmol/L.  
Abbreviations: CGM, continuous glucose monitoring; CI, confidence interval; LS, least squares; MAGE, mean amplitude of glucose excursions; SD, standard deviation.
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in other words, unconscious hypoglycemia. The AEs 
blood ketone body increased, and pruritus genital were 
observed in six and three patients in the canagliflozin 
group, respectively; all of these events were not severe.
Discussion
In this study, patients with type 2 diabetes on triple combina-
tion therapy were randomized to undergo either glimepiride 
dose adjustment or glimepiride dose adjustment and the 
addition of canagliflozin to ongoing treatment. During the 
24-week treatment period, the mean glimepiride dose was 
decreased in both groups due to low glucose levels detected 
by CGM in accordance with the prespecified algorithm. The 
change in DI was −11% in the glimepiride group and 5% in 
the canagliflozin group, with an intergroup difference ratio of 
18%, although this was not statistically significant. HbA1c 
and FPG levels were significantly lower in the canagliflozin 
group than in the glimepiride group. The CGM data, includ-
ing the mean, SD and proportion of time with glucose levels 
in hyperglycemic, normoglycemic and hypoglycemic ranges, 
suggest that canagliflozin improved the daily blood glucose 
profile. A total of 44 and 79 hypoglycemic episodes were 
observed in the canagliflozin group and the glimepiride 
group, respectively. In addition, we found that the change 
in DI was correlated with improvements in glycemic control 
in terms of glucose levels and variability.
The TA-7284-05 study17,29 was used as a reference to 
determine the sample size for the present study. The change 
in DI in the present study was not statistically significant, 
indicating that DI was not improved by treatment with cana-
gliflozin in the current population to the extent expected from 
the TA-7284-05 study (i.e. an improvement by 62%). 
However, the patients enrolled in the present study had a 
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the triple therapy (metformin, teneligliptin, and glimepiride) 
at baseline, in contrast to the TA-7284-05 study (duration of 
diabetes: about 5 years; diet/exercise therapy only). 
Therefore, it may have been difficult to achieve the level of 
improvement in DI seen in the TA-7284-05 study in the 
present study.
We previously reported that medical nutrition therapy 
without pharmacotherapy aided the recovery of DI in patients 
with newly diagnosed type 2 diabetes presenting with 
extreme hyperglycemia and also show the correlation 
between DI and HbA1c.10 Consistently, we found a correla-
tion between the improvements in DI and glucose control in a 
population of patients with more advanced diabetes. A 
number of cross-sectional studies and an interventional 
study have documented an association between beta cell 
function and glycemic variability.30–32 However, in those 
studies, glycemic variability was evaluated by self-monitored 
blood glucose30,31 or CGM under controlled meal 
conditions.32 Unlike these earlier studies, glycemic levels 
and variability were assessed by CGM in real daily-life 
conditions over 2-week periods in the present study. The 
results of our interventional study provide further, novel 
evidence for the association between mean blood glucose 
or glycemic variability and beta cell function in daily life. 
Our previous in vitro studies, which explored the underlying 
mechanisms in beta cell glucotoxicity, revealed that 
E F
G
Figure 3 Correlations between the changes in log(DI) and the changes in HbA1c (A), FPG (B), body weight (C), mean glucose (D), MAGE (E), and proportions of time with 
glucose level in hyperglycemic (≥180 mg/dL, ≥9.99 mmol/L, F) and normoglycemic (>70 to <180 mg/dL, >3.89 to <9.99 mmol/L, G) ranges.  
Note: HbA1c: IFCC value (mmol/mol) = 10.93 × NGSP value (%) − 23.5. Glucose: 1 mg/dL = 0.0555 mmol/L.  
Abbreviations: DI, disposition index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IFCC, International Federation of Clinical Chemistry and Laboratory 
Medicine; NGSP, National Glycohemoglobin Standardization Program.
Dovepress                                                                                                                                                        Takahara et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020:13                                         submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
alleviating glucotoxicity and lipotoxicity is associated with 
improvements in islet gene expression of Pdx1, Mafa, and 
Slc2a2, key factors involved in beta cell function.33,34 Thus, 
it is possible that reducing glucotoxicity may contribute to 
the improvement in beta cell function and better glycemic 
control observed in the current study.
CGM in daily life in the current study revealed frequent 
asymptomatic hypoglycemia despite low doses of glimepir-
ide in patients presenting with hyperglycemia and no obvious 
signs of hypoglycemia at baseline. Accordingly, and some-
what unexpectedly, it was necessary to lower the dose of 
glimepiride, not increase it, in many patients, even in the 
glimepiride group. Hypoglycemia is associated with 
increased cardiovascular risk, cognitive dysfunction, demen-
tia, and vision disorders.35,36 In patients with recurrent hypo-
glycemia, the brain adapts to hypoglycemia such that 
subsequent symptoms manifest at lower plasma glucose con-
centrations, reducing awareness of hypoglycemia.36 
Therefore, it is important to adjust the dose of glimepiride 
to avoid the risk of hypoglycemia. The current findings 
indicate that glimepiride is associated with increased risk of 
hypoglycemia, even when administered at low doses, in 
patients with inadequate glycemic control on the triple ther-
apy and that canagliflozin may improve glycemic control 
without increasing the risk of hypoglycemia in these patients.
AEs other than hypoglycemia that were observed in the 
canagliflozin group only included blood ketone body 
increased and pruritus genital. These AEs have previously 
been documented in patients treated with SGLT2 inhibi-
tors, including canagliflozin, in clinical practice.17–20,29,37 
These AEs were mild in severity in this study. Our results 
demonstrate the tolerability of adding canagliflozin to 
ongoing triple combination therapy.
Limitations of this study include its small sample size, 
the short-term treatment period, and open-label design. The 
sample size was small and did not have sufficient power to 
detect a significant difference in DI in this population. The 
longer-term effects of canagliflozin await confirmation.
In conclusion, adding canagliflozin to the triple therapy 
improved beta cell function by 18%, but it did not reach 
statistical significance. Treatment with canagliflozin was 
associated with improvements in overall glycemic control 
and glycemic variability, with a relatively lower risk of 
hypoglycemia compared with glimepiride dose adjust-
ment. This study also revealed correlations between the 
improvement in beta cell function (change in DI) and 
changes in markers of glycemic control.
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